Drug Prices
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market to lower prices.
The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy solutions.
Eight in 10 U.S. adults say prescription drug costs are 鈥渦nreasonable,鈥 and one in four say their prescription medicines are difficult to afford, according to the latest Kaiser Family Foundation Health Tracking Poll.
Patients and their providers rely on these prescription drugs for treating injury and managing illness. Yet the drug companies and their shareholders have been treating America鈥檚 patients and providers like a piggybank.
The Senate Finance Committee today held the second in a planned series of bipartisan hearings on high prescription drug prices, which featured executives from drug companies AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency鈥檚 Competitive Generic Therapies designation.
Committee Chairman Richard Neal, D-Mass., and Ranking Member Kevin Brady, R-Texas, said they are committed to working on bipartisan reforms to lower drug prices.
The AHA, Federation of 黑料正能量s, and American Society of Health-System Pharmacists today convened a panel of experts on Capitol Hill to discuss how continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay鈥
Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples Act as it was reintroduced yesterday in the new Congress.